What is the difference between Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

PT (Prothrombin Time) and APTT (Activated Partial Thromboplastin Time) are two distinct blood clotting tests that measure different aspects of the coagulation cascade, with PT evaluating the extrinsic and common pathways and APTT assessing the intrinsic and common pathways. The key difference between PT and APTT lies in the coagulation factors they evaluate and the clinical contexts in which they are used. PT measures factors I, II, V, VII, and X, and is commonly used to monitor warfarin therapy and assess liver function, with results often reported as INR (International Normalized Ratio) for standardization 1. APTT, on the other hand, measures factors I, II, V, VIII, IX, X, XI, and XII, and is used to monitor heparin therapy and screen for hemophilia and other bleeding disorders.

Key Differences and Clinical Applications

  • PT typically takes 11-13.5 seconds in healthy individuals and is used to assess the extrinsic pathway, with prolonged PT suggesting issues such as vitamin K deficiency or warfarin effect 1.
  • APTT normally ranges from 25-35 seconds and is used to assess the intrinsic pathway, with prolonged APTT indicating problems such as hemophilia A or B 1.
  • The choice between PT and APTT depends on the clinical context, with PT preferred for monitoring warfarin therapy and APTT preferred for monitoring heparin therapy 1.
  • Both tests are complementary and often ordered together for a comprehensive assessment of coagulation function, especially in patients on anticoagulant therapy or with suspected bleeding disorders 1.

Interpretation and Limitations

  • A normal aPTT and/or PT cannot rule out the effect of direct oral anticoagulants (DOACs), highlighting the need for careful interpretation and consideration of clinical context 1.
  • Viscoelastic coagulation tests, such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), can provide rapid detection of coagulation disorders and may be useful in guiding reversal therapies in patients on DOACs 1.
  • The limitations of PT and APTT in monitoring DOACs underscore the importance of using these tests in conjunction with clinical judgment and other diagnostic tools to ensure optimal patient care 1.

From the Research

Difference between PT and APTT

  • PT (Prothrombin Time) measures the extrinsic pathway of coagulation, whereas APTT (Activated Partial Thromboplastin Time) measures the intrinsic pathway of coagulation 2.
  • PT is used to monitor patients on warfarin therapy, while APTT is used to monitor patients on heparin therapy 3, 4.
  • APTT is affected by warfarin, and the effects of warfarin and heparin on APTT are additive 3.
  • PT and APTT are both used as global screening tests for abnormalities in the coagulation pathways and for monitoring anticoagulant therapy, but they have limitations as they are artificial in vitro systems 5.

Clinical Implications

  • Abnormal PT and APTT results can confound monitoring of anticoagulant therapies, contributing to treatment failure 6.
  • Warfarin can markedly affect APTT, leading to subtherapeutic heparin levels if heparin dose is decreased in response to a high APTT 3.
  • PT and APTT are significantly increased in patients with acute myocardial infarction on anticoagulation therapy, with PT being more sensitive for predicting blood clotting tendency 2.

Monitoring Anticoagulation Therapy

  • Time in the therapeutic range (TTR) can be used to estimate the quality of anticoagulation with continuous unfractionated heparin, using APTT monitoring 4.
  • Different methodologies can be used to estimate TTR, such as percentage of APTT values in range (%aIR) and a modification of the Rosendaal method (mod-Rosendaal) 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.